5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine
Open Access
- 1 June 2002
- journal article
- Published by Elsevier
- Vol. 277 (26), 23800-23806
- https://doi.org/10.1074/jbc.m112100200
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Antisense therapy in oncology: new hope for an old idea?The Lancet, 2001
- Design of nuclease resistant protein kinase cα DNA enzymes with potential therapeutic applicationJournal of Molecular Biology, 2000
- Midkine Inhibits Caspase‐Dependent Apoptosis via the Activation of Mitogen‐Activated Protein Kinase and Phosphatidylinositol 3‐Kinase in Cultured NeuronsJournal of Neurochemistry, 1999
- Nucleic Acid BiotechnologyAnnual Review of Biomedical Engineering, 1999
- Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 MiceAntisense and Nucleic Acid Drug Development, 1997
- Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley ratsToxicology, 1997
- Increased Midkine Gene Expression in Human Gastrointestinal CancersJapanese Journal of Cancer Research, 1995
- Pharmacokinetics of Antisense OligonucleotidesClinical Pharmacokinetics, 1995
- Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted PolyamideScience, 1991
- cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesisBiochemical and Biophysical Research Communications, 1988